219 related articles for article (PubMed ID: 35289116)
1. CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma.
Higashi M; Momose S; Takayanagi N; Tanaka Y; Anan T; Yamashita T; Kikuchi J; Tokuhira M; Kizaki M; Tamaru JI
J Pathol Clin Res; 2022 Jul; 8(4):340-354. PubMed ID: 35289116
[TBL] [Abstract][Full Text] [Related]
2. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
3. Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma.
Wang J; Wang Y; Wan L; Chen X; Zhang H; Yang S; Zhong L
Front Immunol; 2023; 14():1230017. PubMed ID: 37790933
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
[TBL] [Abstract][Full Text] [Related]
5. Implication of immune cell signature of tumor microenvironment in diffuse large B-cell lymphoma.
Yu H; Fu D; Xu PP; Cheng S; Wang L; Zhang YZ; Zhao WL
Hematol Oncol; 2021 Dec; 39(5):616-624. PubMed ID: 34331367
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
7. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
8. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
9. A glycolysis-related gene signatures in diffuse large B-Cell lymphoma predicts prognosis and tumor immune microenvironment.
Cui Y; Leng C
Front Cell Dev Biol; 2023; 11():1070777. PubMed ID: 36755971
[No Abstract] [Full Text] [Related]
10. An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment.
Liang XJ; Fu RY; Wang HN; Yang J; Yao N; Liu XD; Wang L
J Immunol Res; 2021; 2021():5564568. PubMed ID: 34212052
[TBL] [Abstract][Full Text] [Related]
11. Expression of N
Xie Z; Li M; Hong H; Xu Q; He Z; Peng Z
Bioengineered; 2021 Dec; 12(1):6115-6133. PubMed ID: 34482808
[TBL] [Abstract][Full Text] [Related]
12. High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.
Carreras J; Kikuti YY; Hiraiwa S; Miyaoka M; Tomita S; Ikoma H; Ito A; Kondo Y; Itoh J; Roncador G; Martinez A; Colomo L; Hamoudi R; Ando K; Nakamura N
Cancer Sci; 2022 Jan; 113(1):334-348. PubMed ID: 34706126
[TBL] [Abstract][Full Text] [Related]
13. High levels of Tim-3
Zhong W; Liu X; Zhu Z; Li Q; Li K
Int Immunopharmacol; 2021 Jul; 96():107662. PubMed ID: 33864956
[TBL] [Abstract][Full Text] [Related]
14. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.
Ciavarella S; Vegliante MC; Fabbri M; De Summa S; Melle F; Motta G; De Iuliis V; Opinto G; Enjuanes A; Rega S; Gulino A; Agostinelli C; Scattone A; Tommasi S; Mangia A; Mele F; Simone G; Zito AF; Ingravallo G; Vitolo U; Chiappella A; Tarella C; Gianni AM; Rambaldi A; Zinzani PL; Casadei B; Derenzini E; Loseto G; Pileri A; Tabanelli V; Fiori S; Rivas-Delgado A; López-Guillermo A; Venesio T; Sapino A; Campo E; Tripodo C; Guarini A; Pileri SA
Ann Oncol; 2018 Dec; 29(12):2363-2370. PubMed ID: 30307529
[TBL] [Abstract][Full Text] [Related]
15. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
Front Immunol; 2021; 12():732006. PubMed ID: 34745101
[TBL] [Abstract][Full Text] [Related]
16. Role and mechanism of PIM family in the immune microenvironment of diffuse large B cell lymphoma.
Wang C; Chen Q; Luo H; Chen R
World J Surg Oncol; 2023 Mar; 21(1):76. PubMed ID: 36871027
[TBL] [Abstract][Full Text] [Related]
17. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.
Keane C; Tobin J; Gunawardana J; Francis S; Gifford G; Gabrielli S; Gill A; Stevenson W; Talaulikar D; Gould C; Jain S; Birch S; Hertzberg M; Gandhi MK
Eur J Haematol; 2019 Sep; 103(3):200-207. PubMed ID: 31211907
[TBL] [Abstract][Full Text] [Related]
18. CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance.
Qiao LY; Li HB; Zhang Y; Shen D; Liu P; Che YQ
Pharmgenomics Pers Med; 2021; 14():591-599. PubMed ID: 34079334
[TBL] [Abstract][Full Text] [Related]
19. Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.
Xu T; Chai J; Wang K; Jia Q; Liu Y; Wang Y; Xu J; Yu K; Zhao D; Ma J; Fan L; Yan Q; Guo S; Chen G; Chen Q; Xiao H; Liu F; Qi C; Liang R; Li M; Wang Z
Front Oncol; 2021; 11():638154. PubMed ID: 34221962
[TBL] [Abstract][Full Text] [Related]
20. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
Rajnai H; Heyning FH; Koens L; Sebestyén A; Andrikovics H; Hogendoorn PC; Matolcsy A; Szepesi Á
Virchows Arch; 2014 Feb; 464(2):229-39. PubMed ID: 24306958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
